NASDAQ:REGN - Regeneron Pharmaceuticals Stock Price, Forecast & News

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Regeneron Pharmaceuticals declared that its board has initiated a share repurchase program on Tuesday, November 5th 2019, which allows the company to repurchase $1,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to buy up to 2.9% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company's management believes its stock is undervalued.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) posted its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported $6.67 EPS for the quarter, beating analysts' consensus estimates of $5.13 by $1.54. The biopharmaceutical company had revenue of $2.05 billion for the quarter, compared to analysts' expectations of $1.98 billion. Regeneron Pharmaceuticals had a net margin of 28.13% and a return on equity of 24.85%. The firm's quarterly revenue was up 23.2% on a year-over-year basis. During the same period in the previous year, the business earned $5.87 earnings per share. View Regeneron Pharmaceuticals' Earnings History.

Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals will be holding an earnings conference call on Thursday, February 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

20 Wall Street analysts have issued twelve-month target prices for Regeneron Pharmaceuticals' stock. Their forecasts range from $320.00 to $453.00. On average, they expect Regeneron Pharmaceuticals' stock price to reach $390.67 in the next year. This suggests a possible upside of 1.2% from the stock's current price. View Analyst Price Targets for Regeneron Pharmaceuticals.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 11 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Regeneron Pharmaceuticals.

Press coverage about REGN stock has been trending positive recently, InfoTrie reports. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Regeneron Pharmaceuticals earned a daily sentiment score of 2.4 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 7.0 out of 10, meaning that recent press coverage is likely to have an impact on the company's share price in the immediate future. View News Stories for Regeneron Pharmaceuticals.

Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include Netflix (NFLX), Gilead Sciences (GILD), Celgene (CELG), Biogen (BIIB), Alibaba Group (BABA), NVIDIA (NVDA), Tesla (TSLA), Amgen (AMGN), Alphabet (GOOG) and Broadcom (AVGO).

Regeneron Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Hexavest Inc. (0.08%), DNB Asset Management AS (0.06%), Assenagon Asset Management S.A. (0.03%), Rhenman & Partners Asset Management AB (0.02%), Nisa Investment Advisors LLC (0.02%) and State of Alaska Department of Revenue (0.01%). Company insiders that own Regeneron Pharmaceuticals stock include Christopher R Fenimore, George L Sing, Joseph L Goldstein, Michael S Brown, Neil Stahl, P Roy Vagelos and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals.

REGN stock was sold by a variety of institutional investors in the last quarter, including Commerzbank Aktiengesellschaft FI, Rhenman & Partners Asset Management AB, OLD National Bancorp IN, Assenagon Asset Management S.A., Meag Munich Ergo Kapitalanlagegesellschaft MBH, Hexavest Inc., State of Alaska Department of Revenue and Hudson Capital Management LLC. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Christopher R Fenimore, George L Sing, Joseph L Goldstein, Michael S Brown, Neil Stahl, P Roy Vagelos and Sanofi. View Insider Buying and Selling for Regeneron Pharmaceuticals.

REGN stock was bought by a variety of institutional investors in the last quarter, including First National Bank of Omaha, DNB Asset Management AS, Nisa Investment Advisors LLC, Alpine Global Management LLC, First Hawaiian Bank, Diversified Trust Co, Cypress Capital Group and AE Wealth Management LLC. View Insider Buying and Selling for Regeneron Pharmaceuticals.

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of REGN stock can currently be purchased for approximately $385.94.

Regeneron Pharmaceuticals has a market capitalization of $42.37 billion and generates $6.71 billion in revenue each year. The biopharmaceutical company earns $2.44 billion in net income (profit) each year or $19.80 on an earnings per share basis. Regeneron Pharmaceuticals employs 7,400 workers across the globe.View Additional Information About Regeneron Pharmaceuticals.

The official website for Regeneron Pharmaceuticals is http://www.regeneron.com/.

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]